300405.SZ(300405.SZ)

$5.63—

Chart

300405.SZ(300405.SZ)

SHZ

$5.63—

Chart Studio

300405.SZ(300405.SZ)

300405.SZ

Overview Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

8/15/26

LIAONING KELONG FINE CHEMICAL,INC. (300405.SZ)

Saturday

3:58 PM

Thesis: The combination of declining revenues and increased regulatory costs is leading to a more cautious outlook among investors.

Revenue Outlook

Metric	FY2024	FY2025
Revenue	$632M	$544M
Rev. Growth	+13.2%	-13.9%
EPS	$-0.18	$-0.22
EPS Growth	+48.6%	-22.2%
P/E	—	—

What Could Go Wrong

1Recent regulatory changes may increase compliance costs by up to 20%, impacting margins significantly.
2Declining demand for certain chemical intermediates due to market saturation could lead to further revenue declines.
3Regulatory changes that could impose stricter environmental standards
4Technological disruption from alternative chemical production methods
5Increased competition from domestic and international chemical manufacturers
6Price wars leading to margin compression
7High debt levels relative to equity (Debt/Equity of 1.27) could strain financial flexibility
8Negative operating cash flow impacting liquidity

FY2025 Snapshot

Revenue: $544M
Rev. Growth: -13.9%
Gross Margin: 4.5%
Op. Margin: -9.3%
Net Margin: -11.3%
Net Income: $-61M
NI Growth: -22.8%
EPS: $-0.22
1Y Return: -10.4%

300405.SZ Chart

My Notes

"Management has indicated that 'the regulatory environment is becoming increasingly challenging, impacting our cost structure.'"
Moat: The company's competitive advantage is limited due to low differentiation in products and high competition.
Watch: Emerging competitors from Southeast Asia are increasing pressure on pricing and market share.
value - Investors may be attracted by the low valuation metrics despite operational challenges.
Interest rates affect financing costs for capital expenditures and can influence demand for chemical products as businesses adjust spending…
Watch on earnings: Raw material price indices (e.g., crude oil prices), Pharmaceutical industry growth rates in China, Operating cash flow trends.

One Sentence Summary:

The bear case: recent regulatory changes may increase compliance costs by up to 20%, impacting margins significantly.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research note…

First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2024

FY2025

P/E

—

What Could Go Wrong

1Recent regulatory changes may increase compliance costs by up to 20%, impacting margins significantly.

2Declining demand for certain chemical intermediates due to market saturation could lead to further revenue declines.

3Regulatory changes that could impose stricter environmental standards

4Technological disruption from alternative chemical production methods

5Increased competition from domestic and international chemical manufacturers

6Price wars leading to margin compression

7High debt levels relative to equity (Debt/Equity of 1.27) could strain financial flexibility

8Negative operating cash flow impacting liquidity

My Notes

"Management has indicated that 'the regulatory environment is becoming increasingly challenging, impacting our cost structure.'"

Moat: The company's competitive advantage is limited due to low differentiation in products and high competition.

Watch: Emerging competitors from Southeast Asia are increasing pressure on pricing and market share.

value - Investors may be attracted by the low valuation metrics despite operational challenges.

Interest rates affect financing costs for capital expenditures and can influence demand for chemical products as businesses adjust spending…

Watch on earnings: Raw material price indices (e.g., crude oil prices), Pharmaceutical industry growth rates in China, Operating cash flow trends.